Janssen Search
Search results
Johan Verbeeck, DVM
JOHAN VERBEECK, DVM VICE PRESIDENT JANSSEN BUSINESS DEVELOPMENT ONCOLOGY Johan Verbeeck, DVM is Vice President, Janssen Business Development, Oncology where he leads business development planning in support of the Oncology Therapeutic Area. His ...
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
Jun 14, 2024 At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM (14 June 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated ...
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Jul 26, 2024 Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1, 2, 3, 4 In the MARIPOSA-2 study, ...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
May 03, 2024 New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG) – unresponsive high-risk non – muscle ...
Disease Interception Accelerator
Thinking Differently About Healthcare Article Type: World Without Disease Accelerator Research & Development We envision a future where the term “patient” becomes a thing of the past, because intervening and stopping disease from progressing in ...
Data Sciences Overview
The Vision for Data Science at Janssen R&D Data Science and Digital Health are among the most exciting revolutions of our time, transforming how we discover, develop and deliver new therapies and vaccines to advance our ultimate mission of bringing ...
Iqbal Grewal, Ph.D., D.Sc., F.R.C.Path
Iqbal Grewal, Ph.D., D.Sc., F.R.C.Path is Vice President, Head of Immuno-Oncology in the Oncology Therapeutic Area at Janssen Research & Development, LLC. He leads research efforts at Janssen to discover and develop therapeutics that function as ...
Scott White
SCOTT WHITE Company Group Chairman North America Pharmaceuticals Johnson & Johnson Scott White is Company Group Chairman, North America, at the Janssen Pharmaceutical Companies of Johnson & Johnson. A member of the Pharmaceuticals Group Operating ...
Cancer Interception and the Tumor Microenvironment
Cancer Interception and the Tumor Microenvironment “We are intent on understanding what turns healthy cells into cancerous cells and continue to make progress in this area. These critical insights will help us advance medicines to interrupt the process ...
Pulmonary Hypertension Overview
Pulmonary Hypertension At Janssen, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Building on Actelion's 20-year ...